Legend Biotech (NASDAQ:LEGN) CEO Ingrid Zhang Buys 20,000 Shares of Company Stock

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) CEO Ingrid Zhang acquired 20,000 shares of Legend Biotech stock in a transaction that occurred on Tuesday, November 17th. The stock was bought at an average price of $8.16 per share, for a total transaction of $163,200.00. Following the completion of the acquisition, the chief executive officer owned 1,151,860 shares in the company, valued at $9,399,177.60. This trade represents a 1.77% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Legend Biotech Trading Down 5.3%

NASDAQ LEGN traded down $0.85 during trading hours on Friday, reaching $15.25. The company had a trading volume of 3,419,205 shares, compared to its average volume of 2,439,548. The stock has a 50-day moving average of $19.24 and a 200 day moving average of $22.09. Legend Biotech Corporation Sponsored ADR has a 1-year low of $15.15 and a 1-year high of $37.50. The stock has a market capitalization of $2.96 billion, a P/E ratio of -1,523.48 and a beta of 0.55.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Legend Biotech had a negative net margin of 0.02% and a negative return on equity of 0.03%. The business had revenue of $359.50 million during the quarter, compared to analysts’ expectations of $361.46 million. During the same period last year, the business earned ($0.05) earnings per share. The business’s revenue for the quarter was up 32.0% on a year-over-year basis. As a group, sell-side analysts predict that Legend Biotech Corporation Sponsored ADR will post -0.02 EPS for the current year.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors and hedge funds have recently made changes to their positions in LEGN. Assenagon Asset Management S.A. acquired a new stake in Legend Biotech in the second quarter valued at approximately $55,307,000. Squarepoint Ops LLC grew its holdings in Legend Biotech by 60.4% during the 2nd quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock worth $22,216,000 after acquiring an additional 289,772 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Legend Biotech by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after acquiring an additional 119,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Legend Biotech by 343.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock valued at $7,361,000 after purchasing an additional 315,176 shares during the last quarter. Finally, Tidal Investments LLC increased its position in shares of Legend Biotech by 34.0% in the 2nd quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock valued at $6,945,000 after purchasing an additional 61,023 shares during the last quarter. 70.89% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Legend Biotech

Here are a few of the latest headlines about LEGN:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and forecasts Legend Biotech will earn $0.24 per share in FY2026, followed by $1.18 per share in FY2027. A separate report cites a brokerage consensus price target of $50.85. Brokerage consensus price target report
  • Neutral Sentiment: A recent article asks whether a return to profitability changes the investment case, but the available report details do not specify its conclusions. Yahoo Finance article on Legend Biotech’s return to profit
  • Negative Sentiment: HC Wainwright cut its EPS estimates across several upcoming periods: FY2027 to $1.18 from $1.70, Q1 2027 to $0.14 from $0.26, and Q2 2027 to $0.22 from $0.36. It also reduced its Q3 and Q4 2027 forecasts. The broad revisions signal a less favorable earnings outlook and could pressure the shares, although the firm kept its Buy rating. Legend Biotech stock and analyst information

Analyst Upgrades and Downgrades

LEGN has been the topic of a number of research reports. Oppenheimer decreased their price target on Legend Biotech from $40.00 to $25.00 and set a “market perform” rating on the stock in a research note on Wednesday, November 11th. Barclays lowered their price target on Legend Biotech from $68.00 to $61.00 and set an “overweight” rating for the company in a research report on Wednesday, November 11th. Weiss Ratings upgraded shares of Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, November 9th. TD Cowen decreased their price target on shares of Legend Biotech from $29.00 to $24.00 and set a “hold” rating for the company in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded shares of Legend Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, November 14th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.64.

Check Out Our Latest Report on LEGN

Legend Biotech Company Profile

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

Further Reading

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.